PUBLISHER: TechNavio | PRODUCT CODE: 1626161
PUBLISHER: TechNavio | PRODUCT CODE: 1626161
Treatment Resistant Depression Therapeutics Market 2025-2029
The treatment resistant depression therapeutics market is forecasted to grow by USD 2061 mn during 2024-2029, accelerating at a CAGR of 6.1% during the forecast period. The report on the treatment resistant depression therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of depression, focus on rapid-acting antidepressants, and investments in mental health.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 5.8% |
CAGR | 6.1% |
Incremental Value | $2061 mn |
Technavio's treatment resistant depression therapeutics market is segmented as below:
By Distribution Channel
By Type
By Geographical Landscape
This study identifies the emergence of ai in drug development as one of the prime reasons driving the treatment resistant depression therapeutics market growth during the next few years. Also, increase in regulatory approvals and focus on personalized medicine will lead to sizable demand in the market.
The report on the treatment resistant depression therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading treatment resistant depression therapeutics market vendors that include AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Public Ltd. Co., AstraZeneca Plc, Axsome Therapeutics Inc., Eli Lilly and Co., Evotec SE, H Lundbeck AS, Intra-Cellular Therapies Inc, Johnson and Johnson Inc., Numinus Wellness Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sage Therapeutics Inc, Stella MSO LLC dba Field Trip Health, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., and Vistagen Therapeutics Inc. Also, the treatment resistant depression therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: